Biomedical applications of L-alanine produced by Pediococcus acidilactici BD16 (alaD +)

dc.contributor.authorSharma, Anshula
dc.contributor.authorMehta, Vikrant
dc.contributor.authorRani, Suman
dc.contributor.authorNoda, Masafumi
dc.contributor.authorSugiyama, Masanori
dc.contributor.authorChander, Harish
dc.contributor.authorKaur, Baljinder
dc.date.accessioned2024-01-21T10:54:04Z
dc.date.accessioned2024-08-14T07:40:50Z
dc.date.available2024-01-21T10:54:04Z
dc.date.available2024-08-14T07:40:50Z
dc.date.issued2022-01-28T00:00:00
dc.description.abstractAbstract: L-alanine possesses extensive physiological functionality and tremendous pharmacological significance, therefore could be considered as potential ingredient for food, pharmaceutical, and personal care products. However, therapeutic properties of L-alanine still need to be addressed in detail to further strengthen its utilization as a viable ingredient for developing natural therapeutics with minimum side effects. Thus, the present study was aimed to explore the anticipated therapeutic potential of L-alanine, produced microbially using a lactic acid bacterial strain Pediococcus acidilactici BD16 (alaD+) expressing L-alanine dehydrogenase enzyme. The anticipated therapeutic potential of L-alanine was assessed in terms of anti-proliferative, anti-bacterial, and anti-urolithiatic properties. Anti-bacterial assays revealed that L-alanine successfully inhibited growth and in vitro proliferation of important human pathogens including Enterococcus faecalis, Escherichia coli, Klebsiella pneumonia, Staphylococcus aureus, Streptococcus mutans, and Vibrio cholerae in a concentration-dependent manner. Current investigation has also revealed its significant anti-proliferative potential against human lung adenocarcinoma (A549; IC50 7.32�?M) and mammary gland adenocarcinoma (MCF-7; IC50 8.81�?M) cells. The anti-urolithiatic potential of L-alanine was augmented over three different phases, viz., nucleation inhibition, aggregation inhibition, and oxalate depletion. Further, an in vitro cell culture�based kidney stone dissolution model using HEK293-T cells was also established to further strengthen its anti-urolithiatic potential. This is probably the first in vitro cell culture�based model which experimentally validates the immense therapeutic efficacy of L-alanine in treating urolithiasis disease. Key points: � Assessment of therapeutic potential of L-alanine produced by LAB. � L-alanine exhibited significant anti-proliferative and anti-bacterial activities. � L-alanine as potential anti-urolithiatic agent. � 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.en_US
dc.identifier.doi10.1007/s00253-022-11766-9
dc.identifier.issn1757598
dc.identifier.urihttps://kr.cup.edu.in/handle/32116/4203
dc.identifier.urlhttps://link.springer.com/10.1007/s00253-022-11766-9
dc.language.isoen_USen_US
dc.publisherSpringer Science and Business Media Deutschland GmbHen_US
dc.subjectAnti-bacterialen_US
dc.subjectAnti-proliferativeen_US
dc.subjectAnti-urolithiaticen_US
dc.subjectInvestigational drugen_US
dc.subjectKidney stone dissolutionen_US
dc.subjectL-alanineen_US
dc.subjectPediococcus acidilactici BD16en_US
dc.subjectTherapeuticsen_US
dc.titleBiomedical applications of L-alanine produced by Pediococcus acidilactici BD16 (alaD +)en_US
dc.title.journalApplied Microbiology and Biotechnologyen_US
dc.typeArticleen_US
dc.type.accesstypeClosed Accessen_US

Files